1. Dose escalation in radical radio(chemo)therapy for cervical and upper thoracic esophageal cancer with 3DCRT/IMRT (ChC&UES): a multicenter retrospective study.
- Author
-
Zhao XH, Zhang WC, Wang X, Chen JQ, Xu YJ, Zhao KL, Huang W, Qian PD, Liu YT, Ge XL, Xia XJ, Weng CG, Gai CY, Wang HS, Gao HM, Shen WB, and Zhu SC
- Subjects
- Humans, Retrospective Studies, Female, Middle Aged, Male, Aged, Adult, Radiotherapy, Conformal methods, Survival Rate, Aged, 80 and over, Prognosis, Esophageal Neoplasms therapy, Esophageal Neoplasms mortality, Esophageal Neoplasms radiotherapy, Esophageal Neoplasms pathology, Chemoradiotherapy methods, Radiotherapy Dosage, Radiotherapy, Intensity-Modulated methods, Radiotherapy, Intensity-Modulated adverse effects
- Abstract
Background: Cervical and upper thoracic esophageal cancer (ESCA) presents treatment challenges due to limited clinical evidence. This multi-center study (ChC&UES) explores radical radio(chemo)therapy efficacy and safety, especially focusing on radiation dose., Method: We retrospectively analyzed clinical data from 1,422 cases across 8 medical centers. According to the radiation dose for primary gross tumor, patients were divided into standard dose radiotherapy (SD, 50-55 Gy) or high dose (HD, > 55 Gy) radiotherapy. HD was further subdivided into conventional- high-dose group (HD-conventional, 55-63 Gy) and ultra-high-dose group (HD-ultra, ≥ 63 Gy). Primary outcome was Overall Survival (OS)., Results: The median OS was 33.0 months (95% CI: 29.401-36.521) in the whole cohort. Compared with SD, HD shown significant improved survival in cervical ESCA in Kaplan-Meier (P = 0.029) and cox multivariate regression analysis (P = 0.024) while shown comparable survival in upper thoracic ESCA (P = 0.735). No significant difference existed between HD-conventional and HD-ultra in cervical (P = 0.976) and upper thoracic (P = 0.610) ESCA. Incidences of radiation esophagitis and pneumonia from HD were comparable to SD (P = 0.097, 0.240), while myosuppression risk was higher(P = 0.039). The Bonferroni method revealed that, for both cervical and upper thoracic ESCA, HD-ultra enhance the objective response rate (ORR) compared to SD (P < 0.05)., Conclusion: HD radiotherapy benefits cervical but not upper thoracic ESCA, while increasing bone marrow suppression risk. Further dose escalating (≥ 63 Gy) doesn't improve survival but enhances ORR., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF